
New Amsterdam Pharma’s Upcoming Investor Conferences in March: A Profitable Opportunity for Industry Insights
NewAmsterdam Pharma Announces Participation in Upcoming Investor Conferences NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS), a pioneering clinical-stage biopharmaceutical organization, specializing in the development of oral, non-statin medicines for patients with elevated low-density lipoprotein cholesterol (LDL-C) levels, who do not respond adequately or cannot tolerate current therapies for cardiovascular disease (CVD), has recently declared that the…